Within the space of just a few years, several new retinal treatments have been approved for age-related macular degeneration (AMD) and diabetic retinopathy/diabetic macular edema (DR/DME), promising increased durability and better patient outcomes. These conditions can signiícantly impact vision and quality of life for patients. The program will explore the clinical, emotional, and logistical challenges faced by patients, highlight the importance of timely diagnosis and eìective treatment strategies, and emphasize multidisciplinary approaches to optimize patient outcomes and quality of life. Practical insights into improving treatment adherence and shared decision-making will also be covered to support better care delivery. We will also explore regional perspectives on AMD and DR/DME, identify opportunities to improve the quality of care, and highlight collaborative approaches and health plan best practices to enhance patient outcomes.
- Provider:Medical Education Resources
- Activity Link: https://www.impactedu.net
- Start Date: 2025-01-30 06:00:00
- End Date: 2025-01-30 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.5 hours
Nursing: 1.5 hours
Pharmacy: 1.5 hours - Commercial Support: Source: Regeneron Pharmaceuticals, Inc. - Amount: 5500.0 - Is Kind Support: False
- Activity Type: Live Course
- CME Finder Type: Conference
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all